Literature DB >> 16880868

Guidelines for the use of controlled substances in the management of chronic pain.

Sairam Atluri1, Mark V Boswell, Hans C Hansen, Andrea M Trescot, Vijay Singh, Arthur E Jordan.   

Abstract

Controlled substance abuse has increased at an alarming rate. However, available evidence suggests a wide variance in the use of controlled substances, as documented by different medical specialties, medical boards, advocacy groups, and the Drug Enforcement Administration. The primary objective of controlled substance guidelines by American Society of Interventional Pain Physicians (ASIPP) is to provide guidance for the use of controlled substances for the treatment of chronic pain. It is anticipated that these practical guidelines will improve quality of care, patient access, and quality of life. Additional benefits include improved treatment efficiency and efficacy, and cost containment by improving the risk-benefit ratio of treating patients with chronic pain. Further goals of this manuscript are to bring consistency in opioid philosophy among the many diverse groups involved, to improve the treatment of chronic pain patients with medically appropriate controlled substances, and to reduce the incidence of drug diversion. These guidelines also reinforce the need for systematic evaluation and ongoing care of patients with chronic or persistent pain. ASIPP controlled substance guidelines also provide a discussion of the epidemiology of chronic pain, the role of controlled substances in treating chronic pain, various aspects of drug abuse, pharmacological considerations, clinical effectiveness of controlled substances, options for treatment monitoring and drug testing and a review of terminology used in addiction medicine. These guidelines do not constitute inflexible treatment recommendations. It is expected that a provider will establish a plan of care on a case-by-case basis, taking into account an individual patient's medical condition, personal needs, and preferences, and the physician's experience. Based on an individual patient's needs, controlled substance prescribing and treatment different from that outlined here may be warranted. These guidelines do not represent "standard of care."

Entities:  

Year:  2003        PMID: 16880868

Source DB:  PubMed          Journal:  Pain Physician        ISSN: 1533-3159            Impact factor:   4.965


  7 in total

Review 1.  Issues in long-term opioid therapy: unmet needs, risks, and solutions.

Authors:  Steven D Passik
Journal:  Mayo Clin Proc       Date:  2009-07       Impact factor: 7.616

2.  Thermal sensitivity across ages and during chronic fentanyl administration in rats.

Authors:  Jeremiah D Mitzelfelt; Christy S Carter; Drake Morgan
Journal:  Psychopharmacology (Berl)       Date:  2013-07-31       Impact factor: 4.530

3.  Effects of chronic fentanyl administration on physical performance of aged rats.

Authors:  Jeremiah D Mitzelfelt; Jameson P Dupree; Dong-oh Seo; Christy S Carter; Drake Morgan
Journal:  Exp Gerontol       Date:  2010-10-15       Impact factor: 4.032

Review 4.  Opioid misuse in oncology pain patients.

Authors:  Jane C Ballantyne
Journal:  Curr Pain Headache Rep       Date:  2007-08

5.  Cost of opioid medication abuse with and without tampering in the USA.

Authors:  Jeffrey Vietri; Elizabeth T Masters; Alexandra I Barsdorf; Jack Mardekian
Journal:  Clinicoecon Outcomes Res       Date:  2018-08-10

6.  Challenges in using opioids to treat pain in persons with substance use disorders.

Authors:  Seddon R Savage; Kenneth L Kirsh; Steven D Passik
Journal:  Addict Sci Clin Pract       Date:  2008-06

7.  The role of tramadol in current treatment strategies for musculoskeletal pain.

Authors:  Stephan A Schug
Journal:  Ther Clin Risk Manag       Date:  2007-10       Impact factor: 2.423

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.